GleamWall
中文EN

ATTO Attovia Therapeutics, Inc.

Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 2058707 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY—
TTM EPS YoY—
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE—
ROA—
ROIC (approx.)—
Asset turnover—

Leverage & solvency

Liabilities / assets3.4%
Debt / equity0.00x
Current ratio34.66x
Interest coverage—

Cash quality & payout

Operating cash flow / net income—
Accruals ratio—
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q32026-09-302026Q22026-06-302026Q12026-03-312025Q32025-09-302025Q22025-06-302025Q12025-03-31
Income statement
Revenue$0$450,000—$360,000$0—
R&D expense$20.29M$18.95M—$12.32M$13.59M—
SG&A expense$4.73M$3.31M—$3.65M$3.03M—
Operating income-$25.02M-$21.80M—-$15.60M-$16.62M—
Net income-$22.27M-$20.69M-$18.66M-$13.78M-$14.44M-$15.15M
EBITDA-$24.82M-$21.60M—-$15.40M-$16.42M—
EPS (basic)-0.76-4.88—-3.44-3.71—
EPS (diluted)-0.76-4.88—-3.44-3.71—
Weighted avg. shares (diluted)29.37M4.24M—4.00M3.90M—
Balance sheet
Cash & equivalents$115.37M$32.83M—$49.77M$42.65M—
Short-term investments$280.57M$82.30M————
Current assets$404.52M$118.40M————
PP&E, net$3.15M$3.34M————
Total assets$411.82M$128.35M————
Current liabilities$11.67M$12.62M————
Total liabilities$14.08M$15.58M————
Shareholders' equity$397.74M-$145.46M-$125.52M-$90.92M-$75.53M-$61.76M
Shares outstanding45.68M4.53M————
Cash flow statement
Operating cash flow-$25.67M——-$15.16M——
Capital expenditure$17,000——$375,000——
Free cash flow-$25.69M——-$15.53M——
Investing cash flow-$199.75M——$22.27M——
Financing cash flow$307.96M——$13,000——
Depreciation & amortization$200,000$200,000—$200,000$200,000—
Stock-based compensation$1.63M$692,000—$679,000$563,000—

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.